Microbion Corporation of Bozeman, MT, and Microbion Pharma Corp of Vancouver, BC (Microbion), a clinical-stage biopharmaceutical company, has received recommendation from the World Health Organization (WHO) for 'pravibismane' as the International Nonproprietary Name (INN) also commonly known as the generic name, for Microbion's lead broad-spectrum antimicrobial and antibiofilm agent, it was reported on Friday.
The announcement was made by Microbion.
The firm has completed Phase one and early Phase two trials of pravibismane formulated for topical and intrasurgical administration in diabetic foot ulcer infections and orthopaedic device-related infections, respectively. Microbion says that Pravibismane has broad spectrum, antibacterial efficacy against a broad range of pathogens, including multiple priority pathogens or 'superbugs' identified by the US Centers for Disease Control and Prevention (CDC). It has also demonstrated the ability to eradicate microbial biofilms.
;;;
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical